Development of an algorithm for formation of a plasma donor base for producing a standard sample of anti-D antibody


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Relevance. The potency of raw materials, intermediate products and the finished preparation of human anti-D immunoglobulin must be determined in international units. The application of the international standard for anti-D immunoglobulin in the Russian Federation has difficulties associated with the duration of delivery and the need to comply with increased requirements for the conditions of transportation of biological thermolabile substances. In this regard, there is a need for the development of a domestic standard sample for the content of anti-D antibodies and its certification in international units. An integral step in obtaining this standard is the creation of a raw material base, taking into account the requirements for the content of anti-D antibodies in the immune blood plasma of donors. The aim of the study. To develop an algorithm for the selection of plasma donors for the production of a domestic standard sample for the anti-D antibodies content. Material and methods. The data of the information system of transfusiology for the period from january 2015 to december 2020 were analyzed about 510 donors with identified anti-erythrocyte antibodies. Immunohematological tests were performed by gel centrifugation using reagents and a set of equipment manufactured by Bio-Rad Laboratories (Switzerland). The concentration of anti-D antibodies in the blood plasma of donors was calculated in relation to the 2nd WHO international standard for anti-D immunoglobulin, NIBSC 01/572 (Great Britain). Results. It is proposed to use blood plasma of persons naturally immunized to the D-antigen as a substance for the production of a standard sample. As a result of the analysis of the requirements for the analytical range of methods for determining the potency of human anti-D immunoglobulin, it was established that the content of anti-D antibodies in the production pool of plasma for obtaining a standard sample should be at least 3.75 IU/ml. The selection of donors begins with the formation from the transfusion information system of list person with Rh-negative affiliation and identified anti-erythrocyte antibodies based on the results of a medical examination. Potential donors of anti-D plasma sent for immunohematological examination for determine the specificity of antierythrocyte antibodies and the content of anti-D antibodies. The presence of specific antibodies to the D-antigen is the basis for including information about the donor in the forming database. Conclusions. The necessity of creating a domestic standard sample for the content of anti-D antibodies has been proved. An algorithm for the formation of a raw material base for the production of a domestic standard sample has been developed. Using the formulated selection principles, a donor base was created, including 22 women (as of December 2020), in whose plasma the anti-D antibodies content is in the range from 0.1 to 28.5 IU/ml.

全文:

受限制的访问

作者简介

N. Vildanova

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: nikulina@niigpk.ru
Junior Research Scientist, Blood products laboratory

E. Kormshchikova

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: kormschikova@niigpk.ru
Junior Research Scientist, Blood Products Laboratory

E. Butina

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: butina@niigpk.ru
Dr.Sc. (Med.), Head of the Laboratory of Immunohematology

E. Poponina

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: poponinaea@niigpk.ru
Ph.D. (Med.), Research Scientist, Laboratory of Immunohematology

A. Yovdiy

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: yovdiy@niigpk.ru
Ph.D. (Med.), Research Scientist, Laboratory of Immunohematology

F. Sherstnev

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: sherstnev@niigpk.ru
Ph.D. (Med.), Head of the Department of Transfusion and Processing of Hematopoietic Blood Stem Cells

K. Vorobiev

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: vorobiev@niigpk.ru
Dr.Sc. (Biol.), Deputy Director for Research

I. Paramonov

Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agence

Email: paramonov@niigpk.ru
Dr.Sc. (Med.), Director

E. Kudasheva

Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation

Email: kudasheva@expmed.ru
Ph.D. (Med.), Head of the Laboratory of Immunoglobulins and Blood Products

A. Tarasov

Kirov Regional State-Financed Healthcare Institution Kirov Center of Blood

Email: kospk@yandex.ru
Head physician

参考

  1. Минеева Н.В., Пашкова И.А., Кробинец И.И., Сысоева Е.А. Аллосенсибилизация к антигенам эритроцитов (обзор литературы). Онкогематология. 2015; 4(10): 60-65.
  2. Донское С.И. Группы крови системы Rhesus. Теория и практика. М.: ВИНИТИ РАН. 2005; с. 392.
  3. Ветров В.В., Иванов Д.О., Черминых С.В. Заболеваемость гемолитической болезнью новорожденных при резус-конфликте и ее профилактика. Проблемы женского здоровья. 2016; 3(11): 52-63.
  4. Павлова Н.Г. Анти-D-иммунопрофилактика. Журнал акушерства и женских болезней. 2015; 64(3): 52-57.
  5. Fox B., Sharp G., Atkinson E., Roberts G., Rigsby P., Studholme L. The third international standard for antiDD immunoglobulin: international collaborative study to evaluate candidate preparations. Vox sanguinis. 2019; 7: 740-748.
  6. Shaz B.H., Hillyer C.D., Reyes G.M. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspect, 3rd ed. Philadelphia, PA: Elsevier, 2018; p. 1048.
  7. Ожерельева М.А., Е.Н. Кравченко, Ветров В.В., Иванов Д.О., Куклина Л.В. Профилактика гемолитической болезни плода и новорожденного и ее тяжелых форм при резус-конфликте (обзор литературы). Детская медицина Северо-Запада. 2015; 6(3): 42-48.
  8. Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология» (за исключением использования вспомогательных репродуктивных технологий): приказ Минздрава России от 01.11.2012 N 572н. Доступ из справочно-правовой системы «Гарант» (дата обращения: 21.08.2020).
  9. Assay of human anti-D immunoglobulin 01/2008:20713 / European Pharmacopoeia 9.0 [Электронный ресурс]. URL: http://online6.edqm.eu/ep900/ (дата обращения: 21.08.2020).
  10. Приказ Министерства здравоохранения Российской Федерации от 09 января 1998 г. № 2 «Об утверждении инструкций по иммуносерологии».
  11. Бутина Е.В., Минеева Н.В., Зайцева Г.А, Попонина Е.А, Йовдий А.В. Аллоиммунизация к антигенам эритроцитов у пациентов с гематологическими и онкогематологическими заболеваниями. Трансфузиология. 2019; 2(21): 43-46.
  12. Шведова Е.В., Кудашева Э.Ю. Климов В.И. Методы оценки специфической активности препаратов иммуноглобулина человека антирезус Rho(D): современное состояние проблемы. Иммунология. 2020; 41(3): 256-261.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2021
##common.cookie##